ArticleAnnals of surgery2025
Long-Term Outcomes of Patients Undergoing Two-Stage Hepatectomy For Extensive Colorectal Liver Metastasis Treated With Perioperative Hepatic Artery and Systemic Chemotherapy.
Article in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The evolving landscape of colorectal liver metastasis management: from resection to transplantation - a narrative review.World journal of surgical oncology · 2026Review
- Pushing the boundaries of surgical resectability in colorectal liver metastases: the advancing role of two-stage hepatectomy.Hepatobiliary surgery and nutrition · 2026Article
- Revisiting the two-stage hepatectomy and hepatic arterial infusion chemotherapy for colorectal liver metastases: insights and long-term outcomes from a large cohort.Hepatobiliary surgery and nutrition · 2026Article
- Evolution of two-stage hepatectomy: 25 years of modifications and lessons learned.Hepatobiliary surgery and nutrition · 2026Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
objectiveThis study analyzed outcomes and clinical differences between patients who completed or failed TSH (cTSH or fTSH), and evaluated predictive factors for cTSH.
backgroundTwo-stage hepatectomy (TSH) is a well-recognized treatment for extensive colorectal liver metastases (CRLM).
methodsA retrospective review of a prospective database identified patients who underwent TSH for extensive CRLM not amenable to a single resection. Patients who submitted to hepatectomy for recurrent CRLM and/or were treated with ablative techniques only, were excluded.
resultsOut of 183 (7%) CRLM patients who underwent an initial hepatectomy for TSH, 127 (69%) completed the treatment (cTSH). Median overall survival (OS) after the first hepatectomy was 45 months for the entire cohort, 20.6 months for fTSH, and 65.3 months for cTSH patients. fTSH was due to disease progression. The vast majority of cTSH patients received systemic chemotherapy between stages, including hepatic arterial infusion chemotherapy (HAIC). Compared with cTSH, fTSH patients had more frequent extrahepatic disease (EHD), larger CRLM, more frequent metachronous metastases, and lower pathologic response at first resection. CRLM >5 cm, EHD prior or at the time of the first hepatectomy, and a tumor response ≥70% to neoadjuvant chemotherapy were independently associated with a cTSH.
conclusionTSH with perioperative systemic chemotherapy and HAIC in patients with extensive CRLM is associated with excellent oncologic outcomes in patients who complete the resection. EHD, larger tumor size, and lower pathologic response rate were associated with fTSH.
Indexed as
Identifiers
40742184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.